KnowBreastCancer StopBreastCancer Learn the Facts. Know the Evidence. Become an Advocate. Brought to you by NBCC
 

Cigarette Smoking and the Risk of Breast Cancer

Study Design: Prospective cohort study of Nurses’ Health Study participants Study Eligibility: Female nurses aged 30 to 55 and living in the 11 most populous states in the US in 1976. Women who did not have prevalent invasive or in situ breast cancer or other cancers and who provided information on smoking in 1976, the […]

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase III trial

Study Design: Phase III, multinational randomized controlled trial. Women were randomly assigned in a 1:1 ratio to open-label exemestane alone or following tamoxifen (sequential treatment) for 5 years with disease-free survival as a primary endpoint. Study Eligibility: Postmenopausal women (median age 64 years, range 35-96) with hormone-receptor-positive breast cancer. Other inclusion criteria included invasive tumors […]

Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

Study Design: Prospective cohort study of patients enrolled in the Carolina Breast Cancer Study (CBCS). Patients were categorized into tumor subtypes based on the expression of estrogen receptor (ER), progesterone receptor (PR), HER2, HER1, and cytokeratin 5/6 (CK5/6) and followed for a median of 9 years for breast cancer death. Study Eligibility: Invasive breast cancer […]

Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype

Study Design: Cohort study exploring the ability of MRI examinations to monitor response to neoadjuvant chemotherapy in different subtypes of breast cancer. Study Eligibility: Patients with invasive breast cancer greater than 3cm and/or with at least one tumor-positive lymph node who received neoadjuvant chemotherapy (NAC) between 2000 and 2008 in two prior randomized studies. Inclusion […]

Anti-angiogenesis Therapy

What is the impact on length and quality of life? Could treatment be leading to more invasive tumor growth? Disturbing possibility – anti-angiogenesis agents may promote more invasive tumor growth In March 2009, the results from a study in mouse models suggested a disturbing possibility–that although anti-angiogenesis agents may initially shrink tumors, they may later […]

NBCC responds to ODAC vote on Avastin®

NBCC made the case in 2008 that accelerated approval for bevacizumab (Avastin®) was lowering the bar on drug approval. There was no evidence the drug extended the lives of breast cancer patients, and some evidence it increased the risk of harm. The FDA granted accelerated approval on the basis of a clinical trial showing an […]